Limitations of current prophylaxis against influenza virus infection

American Journal of Therapeutics

Volumn 14, Issue 5, 2007, Pages 449-454

  Guralnik, Mario ^a,c   Rosenbloom, Richard A ^b   Petteruti, Michael P ^b   LeFante, Carolyn ^a  

^a Synergy Research Inc   (United States)

^b Quigley Pharma   (United States)

^c NONE   (United States)

Author keywords

Avian; Influenza; Vaccine

Indexed keywords

ADAMANTANE; AMANTADINE; ANTIINFECTIVE AGENT; CATECHIN; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; HERBACEOUS AGENT; INFLUENZA VACCINE; NATURAL PRODUCT; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

EPIDEMIC; FATALITY; FLU LIKE SYNDROME; GENETIC REASSORTMENT; HALLUCINATION; HEALTH PROGRAM; HONG KONG; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; INSOMNIA; MORTALITY; MUTANT; NAUSEA; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VACCINATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION PROGRAMS; INFECTION CONTROL; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PHYTOTHERAPY; PLANT PREPARATIONS; POULTRY;

EID: 34748861507     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3180a5e7d6     Document Type: Review

References (44)

1. Lahariya C, Sharma AK, Pradhan SK. Avian flu and possible human pandemic. Indian Pediatr. 2006;43:317-325.
2. Wu TZ, Huang LM. Avian influenza. Chang Gung Med J. 2005;28:753-757.
3. Liu J-P. Avian influenza: a pandemic waiting to happen? J Microbiol Immunol Infect. 2006;39:4-10.
4. Wong SSY, Yuen K-Y. Avian influenza virus infections in humans. Chest. 2006;129:156-168.
5. Sandhu SK, Mossad SB. Influenza in the older adult: indications for the use of vaccine and antiviral therapy. Geriatrics. 2001;56:43-44, 47-48, 51.
6. Chow A, Ma S, Ling AE, et al. Influenza-associated deaths in tropical Singapore. Emerg Infect Dis. 2006;12:114-121.
7. Perez DR, Sorrell EM, Donis RO. Avian influenza: an omnipresent pandemic threat. Pediatr Infect Dis J. 2005;24(Suppl):S208-S216.
8. Fauci AS. Pandemic influenza threat and preparedness. Emerg Infect Dis. 2006;12:73-77.
9. Bell DM, World Health Organization Writing Group. Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis. 2006;12:88-94.
10. Cooper BS, Pitman RJ, Edmunds WJ, et al. Delaying the international spread of pandemic influenza. PLoS Med. 2006;3:e212.
11. Jones EW. "Co-operation in all human endeavour": quarantine and immigrant disease vectors in the 1918-1919 influenza pandemic in Winnipeg. Can Bull Med Hist. 2005;22:57-82.
12. Greenberg HB, Piedra PA. Immunization against viral respiratory disease: a review. Pediatr Infect Dis J. 2004;23(Suppl):S254-S261.
13. Lee C-W, Suarez DL. Avian influenza virus: prospects for prevention and control by vaccination. Anim Health Res Rev. 2005;6:1-15.
14. Centers for Disease Control and Prevention. Key facts about avian influenza (bird flu) and avian influenza A (H5N1) virus. 2006. Available at: http://www.bt.cdc. gov/scripts/emailprint/print.asp. Accessed July 10, 2006.
15. Center for Infections Disease Research & Policy. Avian influenza (bird flu): implications for human disease. 2006. Available at: http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/biofacts/ avflu_human.html. Accessed July 10, 2006.
16. Maassab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol. 1999;9:237-244.
17. Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 2004;103:177-185.
18. Demicheli V, Rivetti D, Deeks JJ, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2004;3:CD001269.
19. Nichol KL. Complications of influenza and benefits of vaccination. Vaccine. 1999;17(Suppl 1):S47-S52.
20. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J. 2001;17:1282-1293.
21. Fock R, Bergmann H, Bussmann H, et al. Conceptional considerations for a German influenza pandemic preparedness plan. Med Microbiol Immunol (Berl). 2002;191:191-195.
22. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159-1169.
23. Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366:1165-1174.
24. Pinto LH, Lamb RA. Understanding the mechanism of action of the anti-influenza virus drug amantadine [letter]. Trends Microbiol. 1995;3:271.
25. Duff KC, Ashley RH. The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. Virology. 1992;190:485-489.
26. Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367:303-313.
27. McGeer AJ, Lee W, Loeb M, et al. Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults. Infect Control Hosp Epidemiol. 2004;25:955-961.
28. Yuen KY, Wong SS. Human infection by avian influenza A H5N1. Hong Kong Med J. 2005;11:189-199.
29. Alymova IV, Taylor G, Portner A. Neuraminidase inhibitors as antiviral agents. Curr Drug Targets Infect Disord. 2005;5:401-409.
30. Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7:iii-170.
31. Lynd LD, Goeree R, O'Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. Pharmacoeconomics. 2005;23:1083-1106.
32. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4:107-116.
33. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-765.
34. Li Y, Ooi LSM, Wang H, et al. Antiviral activities of medicinal herbs traditionally used in southern mainland China. Phytother Res. 2004;18:718-722.
35. Ma S-C, Du J, But PP-H, et al. Antiviral Chinese medicinal herbs against respiratory syncytial virus. J Ethnopharmacol. 2002;79:205-211.
36. Song J-M, Lee K-H, Seong B-L. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005;68:66-74.
37. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr. 1997;37:693-704.
38. Imanishi N, Tuji Y, Katada Y, et al. Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells. Microbiol Immunol. 2002;46:491-494.
39. Weber JM, Ruzindana-Umunyana A, Imbeault L, et al. Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res. 2003;58:167-173.
40. Chang L-K, Wei T-T, Chiu Y-F, et al. Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate. Biochem Biophys Res Commun. 2003;301:1062-1068.
41. Cheng HY, Lin CC, Lin TC. Antiviral properties of prodelphinidin B-2 3′-O-gallate from green tea leaf. Antivir Chem Chemother. 2002;13:223-229.
42. Lau JTF, Leung PC, Wong ELY, et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. J Altern Complement Med. 2005;11:49-55.
43. Scaglione F, Cattaneo G, Alessandria M, et al. Efficacy and safety of the standardised ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold. Drugs Exp Clin Res. 1996;22:65-72.
44. Chen X, Wu T, Liu G. Chinese medicinal herbs for influenza: a systematic review. J Altern Complement Med. 2006;12:171-180.